Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Hee Sun ParkDa-Hye LeeDa Hyun KangMin-Kyung YeoGoeun BaeDahye LeeGeon YooJu-Ock KimEunyoung MoonYang Hoon HuhSang-Hee LeeEun-Kyeong JoSang Yeon ChoJeong Eun LeeChaeuk ChungPublished in: Cancer medicine (2021)
Finally, we suggest that targeting YAP-p62 signaling axis can be useful to suppress the EGFR-TKI-resistant lung cancer. Therefore, drug repurposing of verteporfin for lung cancer treatment may be valuable to consider because it can inhibit critical targets: p62, YAP, and PD-L1 at the same time.